Elicio Therapeutics (NASDAQ:ELTX – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.14, FiscalAI reports.
Elicio Therapeutics Stock Performance
Elicio Therapeutics stock traded up $0.11 during mid-day trading on Friday, reaching $1.51. The company had a trading volume of 756,123 shares, compared to its average volume of 285,067. The company has a quick ratio of 2.77, a current ratio of 2.77 and a debt-to-equity ratio of 1.20. Elicio Therapeutics has a 52 week low of $1.25 and a 52 week high of $16.00. The company has a 50 day moving average of $1.91 and a 200-day moving average of $6.58. The firm has a market cap of $40.91 million, a price-to-earnings ratio of -0.81 and a beta of 1.64.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on ELTX shares. Wall Street Zen raised Elicio Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. HC Wainwright reaffirmed a “buy” rating on shares of Elicio Therapeutics in a report on Tuesday, August 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Elicio Therapeutics in a report on Tuesday, October 27th. Finally, B. Riley Financial dropped their price target on Elicio Therapeutics to $8.00 and set a “buy” rating on the stock in a research report on Thursday, September 24th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Elicio Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.
Check Out Our Latest Analysis on Elicio Therapeutics
About Elicio Therapeutics
Elicio Therapeutics, Inc (NASDAQ: ELTX) is a clinical-stage biotechnology company developing immunotherapies designed to activate the immune system against cancer. The company’s approach is based on its proprietary Amphiphile technology, which is intended to direct vaccine components and immune-stimulating agents to lymph nodes, where important immune responses are initiated.
Elicio’s lead program is ELI-002, a therapeutic cancer vaccine being developed for patients with tumors containing mutations in the KRAS gene.
Read More
- Five stocks we like better than Elicio Therapeutics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Elicio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elicio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
